Can Technology bring Clinical Trials back on Track during COVID-19?
Summary
With most regulatory bodies also accepting this state of affairs, companies are now receiving guidelines on managing protocol changes and data collection methods. A geriatric or immunity-compromised patient infected with the virus would affect the standard assumptions made with regard to the risk of mortality when designing another study, if not tested. Many other regulatory bodies (like the MHRA in the United Kingdom and EMA in Europe are also advocating similar modifications to trial protocols. Using the CTOS, a clinical trial sponsor can be assured of receiving continuous streams of qualified data and obtain meaningful insight in real-time into a trial’s performance to maintain oversight as well as to take timely decisions. The CTOS empowers clinical stakeholders to mitigate risks and seize the opportunity in the most efficient manner at a reduced cost.
Classifications
AskAI Classifications
LabelsLinked Companies
